Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06174753
PHASE3

Dapagliflozin in STEMI

Sponsor: Ottawa Heart Institute Research Corporation

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Official title: The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

256

Start Date

2025-01-20

Completion Date

2027-12

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg daily X 7 days

DIAGNOSTIC_TEST

CMR

CMR 3-5 days post randomization

Locations (1)

University of Ottawa Heart Institute

Ottawa, Ontario, Canada